vendredi 10 janvier 2014


cliquez pour agrandir

Le SPDR S&P Biotech ETF s'envole grâce à Intercept Pharmaceuticals ICPT.nasdaq et son traîtement efficace d'une maladie du foie.
Le stock est passé de 75$ à 490$ en quelques jours.

Voilà qu'il y a dans ce ETF des bio-pharmas qui peuvent faire parler d'elles en 2014....

....en voici 3

Arena Pharmaceuticals ARNA.q Arena’s approved obesity drug Belviq has started to show promise in recent weeks and Jefferies has a $12 price target on the shares while Thomson/First Call sees $8.Split the difference and call that $10 and Arena still offers significant upside from Thursday’s close just over $6. The stock is almost 1.5% of XBI’s weight.
Then there is Galena Biopharma GALE.q , which  Wall Street said “may be the home run that biotech investors are looking for. The web site went on to note that Galena could be a takeover target and that volume has recently been increasing in the name. The latter point is certainly accurate as Galena’s turnover was more than triple the daily average Thursday. The stock is XBI’s third-largest holding at a weight of 2.11%.
Novavax NVAX.q has six drugs currently in trial, a $7 price target from Piper Jaffray and a consensus target of $10,  Wall Street. Split the difference and call that $8.50 and Novavax could offer about 60% upside from Thursday’s close of $5.18. Novavax accounts for almost 1.9% of XBI’s weight.

Aucun commentaire: